Search results
Found 30397 matches for
Two key treatments do not halt diabetes in people with early signs of the disease, a large study has found. Researchers said the results showed the only way to ensure future health in people at high risk of diabetes is exercise and a healthy diet. Trials in more than 9,000 people also found no reduction in future heart problems in people prescribed two drug treatments compared with dummy pills. In the trial, researchers in the US and UK looked at whether using a drug that lowers blood pressure or a drug which lowers blood sugar could be used to stop diabetes developing in high-risk patients. But the results, from patients in 40 countries, found no great difference in how many people went on to get diabetes when prescribed either drug compared with a dummy pill. Neither did the drugs prevent future heart attacks and strokes, which are dangerous complications of the condition.
Neubauer Group: Oxford Centre for Clinical Magnetic Resonance Research
OCMR uses sophisticated cardiac MR imaging and spectroscopy methods to phenotype cardiovascular disease – in small-scale proof-of-principle studies, large-scale multicentre clinical trials and ultra-large scale population imaging programmes. As well as running their own research programmes, OCMR serves as a collaboration partner to any group wanting to strengthen their clinical research with state of the art non-invasive phenotyping tools.
How to find us
How to find the Diabetes Trials Unit
Publications
DTU Publications
Tyler Group: Development and Application of Cardiac Magnetic Resonance Imaging and Spectroscopy
Using metabolic imaging to transform our approach to disease detection and treatment.
EVAREST (Echocardiography - Value and Accuracy at Rest and Stress)
EVAREST is CCRF-led multi-centre trial which aims to identify and validate novel blood and imaging biomarkers of potential value for consistent and accurate interpretation of stress echocardiography.
DPhil research opportunities
Find out about DPhil Research Opportunities available in 2020.